Amgen CEO Bradway On Deals: Good (Smaller) Opportunities Are Vast

J.P. Morgan Q&A Illuminates Market Dynamics

Amgen is enthusiastic about deals of all sizes, including a new Arrakis collaboration, and is interested in large transactions like its Otezla buy – but Bradway said right-priced opportunities are fewer and farther between. 

Vast prairie and forest in beautiful autumn
In the vast deal landscape, smaller deals are easier to find • Source: Alamy

The biggest question going into the J.P. Morgan Healthcare Conference every year is which big company is going to announce a large acquisition. Amgen, Inc. CEO Robert Bradway’s answer on 11 January at this year’s meeting is that there are not many opportunities out there for larger transactions at a feasible price, but there is a lot of smaller firms with technology that can help the company boost its longer-term research and development goals, like Arrakis Therapeutics.

Amgen and Arrakis announced prior to Bradway’s J.P. Morgan presentation that the companies entered into a research collaboration for the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.